ProfileGDS5678 / 1427433_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 66% 65% 62% 67% 66% 64% 63% 65% 65% 65% 65% 67% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9170865
GSM967853U87-EV human glioblastoma xenograft - Control 23.9680366
GSM967854U87-EV human glioblastoma xenograft - Control 33.9136365
GSM967855U87-EV human glioblastoma xenograft - Control 43.7055162
GSM967856U87-EV human glioblastoma xenograft - Control 54.0036667
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.0103966
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9086164
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.790163
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.965
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8808665
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9005265
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9141565
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0479967
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1888468